Clay Siegall is the Chairman of the Board and CEO of Seattle Genetics, Inc. He enjoys spending some of his time linking to articles he finds of interest on his blog. A recent NPR article he linked to describes how a tiny fish has an opioid-like venom that enables it to escape predators. This fish, called the Fangblenny (due to its huge fangs in comparison to its body), can carve up larger fish in the blink of an eye. When it is eaten by another fish, it releases this venom which disorients the fish while the Fangblenny uses its fangs to bite its way out of the fishes mouth. For this reason, the Fangblenny is called the jerk of the sea.
Another interesting article that Dr. Siegall linked to is about a paralyzed man who, equipped with the latest technology, can control one of his arms and hands using his mind. Bill Kochevar, 56, was paralyzed in a biking accident in his 40’s. The device he uses to control his arm and hand, the BrainGate2, can detect signals in the area of the brain that controls those body parts after he had two electrode arrays surgically installed in his brain.
Due to Dr. Clay Siegall, Seattle Genetics is at the forefront of cancer drug research. He co-founded the company in 1997 in order to focus research on antibody-drug conjugates role in cancer drug therapies. He has also been the Director of Ultragenyx Pharmaceuticals, Inc. since 2014 and the Director of Alder Biopharmaceuticals, Inc since 2005. Another biotechnology company Dr. Clay Siegall is associated with is Mirna Theapeutics, Inc., where he has been on on its Board of Directors since 2013. He earned his BS from the University of Maryland and his Ph.D. from George Washington University.
During his career, Dr. Siegall has written more than 70 scientific publications that pertain to cancer research. He also holds 15 patents including one that is a method for the treatment of immune disorders.